Quality of life assessments at 3 months or later (higher is favored) · people with primary macula‐involving rhegmatogenous retinal detachments
It is very uncertain whether face‐down positioning changes quality of life assessments at 3 months or later (higher is favored) compared with other positioning (very low certainty).
1 finding from 1 review
Mean change from baseline in quality of life score (NEI VFQ‐25 instrument) · adults with low vision (people with AMD)
1 finding from 1 review
Quality of life measures(measured on the EQ‐5D; higher = better) (at 12 months) · participants with primary angle‐closure glaucoma
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Quality of life Measured using the NEI‐RQL‐42. Higher scores are better quality of life. · school‐age children and adolescents
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Vision‐related quality of life · people with cataract and age‐related macular degeneration
1 finding from 1 review
QoL · people with BRVO
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · people with BRVO
1 finding from 1 review
QoL · macular oedema secondary to branch retinal vein occlusion
1 finding from 1 review